The Gene Therapy Starting Materials Market was valued at USD 1.85 billion in 2024 and is expected to reach USD 7.53 billion by 2032, with a CAGR of 19.21%. The US market was valued at USD 750.45 million in 2024, projected to reach USD 3040.49 million by 2032.

Research on gene therapy treatments for rare diseases is rapidly growing, leading to increased demand for starting materials. New manufacturing technologies, patient-centric treatments, and positive regulatory changes are boosting investments in the sector.

The viral vector segment accounted for 43.94% market share in 2024, with high gene transfer efficiency and stable gene expression driving growth. Plasmid DNA is the fastest-growing segment, with a 19.82% CAGR, gaining importance as a viral vector precursor.

North America led the market with a 47.60% share in 2024, driven by advanced healthcare systems and high R&D investments. Asia Pacific is the fastest-growing region, with a 20.15% CAGR, fueled by biotech investments and government support.

Recent advancements include Aldevron’s ultra-pure plasmid DNA platform and Touchlight Genetics’ partnership with OXGENE for scalable AAV gene therapy platforms. The report offers insights on demand trends, end-user utilization, manufacturing capacity, regulatory compliance, pricing, and strategic partnerships. The Gene Therapy Starting Materials Market is projected to grow significantly, with a market size of USD 1.85 billion in 2024 increasing to USD 7.53 billion by 2032 at a CAGR of 19.21%. Key segments include product type, stage, application, and end user. Regional analysis covers North America, Europe, Asia Pacific, Middle East & Africa, and Latin America.

SNS Insider, a leading market research and consulting agency, provides clients with accurate market data, consumer insights, and opinions to make confident decisions in changing circumstances. Using various techniques like surveys and focus groups globally, they aim to equip clients with the knowledge they need to navigate the market effectively.

Read more at GlobeNewswire.: Gene Therapy Starting Materials Market to Grow to USD 7.53